ArticleBMC cancer2026
Efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a retrospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcurrent chemoradiotherapy (CCRT) is the standard treatment for unresectable esophageal squamous cell carcinoma (ESCC). However, its local control rate and overall survival (OS) gain are limited, resulting in a 5-year survival rate of only 20%. Nevertheless, combined immunotherapy (IT) and chemotherapy has demonstrated efficacy in patients with advanced esophageal cancer. This study explored a novel therapeutic strategy and aimed to evaluate the efficacy and safety of CCRT + IT versus CCRT alone in patients with locally advanced unresectable ESCC.
methodsIn this retrospective cohort study, data from 106 patients with locally advanced ESCC who underwent CCRT at the Department of Radiotherapy of the First Affiliated Hospital of Guangxi Medical University, between July 2019 and December 2022, were collected and analyzed. Among them, 60 patients received CCRT combined with IT (CCRT + IT group) and 46 patients received CCRT only (CCRT group). The prognosis and adverse events (AEs) were compared between the two groups.
resultsThe baseline clinical characteristics were similar between the CCRT + IT and CCRT groups. However, the objective response rate (ORR) of the primary tumor was significantly better in the CCRT + IT group than in the CCRT group (76.7% vs. 52.2%; p = 0.008). Compared with the CCRT group, the 1-year progression-free survival (PFS) rate and median PFS were significantly higher in the CCRT + IT group (1-year PFS: 66.7% vs. 41.3%, p = 0.009; median PFS: 17.1 months vs. 9.8 months, p = 0.030). Additionally, both the OS rate and median OS were higher in the CCRT + IT group than in the CCRT group (1-year OS: 80.0% vs. 58.7%, p = 0.017; median OS: 19.6 months vs. 14.2 months, p = 0.087). The incidence of grade ≥ 3 AEs was low and did not significantly differ between groups.
conclusionsCCRT + IT is a promising treatment for locally advanced ESCC, offering remarkable efficacy and manageable toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.